Trial Search Results
Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment
To characterize the molecular and cell biology of the tumor cells in lymphoma. The mechanism of monoclonal antibody treatment by rituximab or epratuzumab will also be examined.
Stanford is currently not accepting patients for this trial.
Collaborator: National Institutes of Health (NIH)
- Drug: Rituximab
- Drug: Epratuzumab
Inclusion Criteria:Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study